So, AIM ImmunoTech Inc. (AIM) shares decided to take a little nap on Friday. This comes after the stock more than doubled recently, which is the kind of move that tends to leave everyone a bit breathless. The catalyst for that wild ride? The company just got the final thumbs-up from the Japan Patent Office for a key patent related to its cancer treatment, Ampligen.

What Exactly Did Japan Approve?

Let's break down the patent. It covers using AIM's drug, Ampligen, in combination with what are known as checkpoint inhibitors—specifically, drugs that target PD-1 or PD-L1. Think of big names like Merck's (MRK) Keytruda or Bristol Myers Squibb's (BMY) Opdivo. The idea is to use Ampligen alongside these blockbuster immunotherapies to treat various cancers, with pancreatic cancer called out as a specific application. The protection from this patent is locked in for a good long while, running through December 20, 2039.

This final approval wasn't a surprise; it came after a mandatory six-month waiting period following an initial grant back in September 2025, allowing for any potential opposition. No opposition emerged, so the patent is now fully official.

Building a Global Moat

This isn't a one-off for AIM. The Japan patent neatly complements an existing U.S. patent for similar combination therapies that expires in August 2039. The company also holds rights in Europe (specifically in the Netherlands) covering Ampligen with drugs like Keytruda, Opdivo, and AstraZeneca's Imfinzi. In short, AIM is methodically building a global intellectual property fortress around its core technology.

"AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy," said Thomas K. Equels, the company's CEO. The message is clear: this is about more than just a patent; it's a strategic piece in tackling a devastating disease.

Where Does the Stock Stand Now?

After that explosive move, the stock is in a bit of a technical tug-of-war. On one hand, it's trading about 12.9% above its 20-day simple moving average (around 93 cents vs. 83 cents). On the other, it's still sitting roughly 28% below its 100-day moving average. That divergence tells you the recent pop was sharp, but the stock has a long way to go to recover its longer-term trend—even though it's up a staggering 606.70% over the past year.

The stock's trading range is vast, from a high of $20.33 down to a low of 6 cents. Currently, it's much closer to the lower end of that spectrum, having retraced from prior peaks.

Looking at momentum indicators paints a mixed picture. The Relative Strength Index (RSI) is at 51.99, which is smack in the middle of neutral territory—no extreme bullish or bearish pressure there. Meanwhile, the MACD indicator is at -0.0643, which is above its signal line (-0.0984). That's considered a bullish setup because it suggests downward momentum is slowing and could be reversing, even though the indicator itself is still negative.

So, you have neutral RSI and a budding bullish MACD. Traders often watch key levels in these situations. For AIM, the immediate ceiling to watch is the $1.00 mark, while a key floor of support sits around 50 cents.

As of the latest data, AIM ImmunoTech shares were down 1.09%, trading at $0.9050.